Mineralys Therapeutics, Inc.
0 products tracked · names used in filings: Mineralys Therapeutics, Inc.
Upcoming milestones
lorundrostat: PDUFA target action date (hypertension in combination with other antihypertensive drugs)
Mineralys Therapeutics, Inc. (MLYS); lorundrostat; NDA; status: set; "Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update – Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant…"; filed 2026-11-04 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.